0.9779

2.93% +0.0278

YS Biopharma Co Ltd (YS)

Overview News Price History Discussions Forecast

YS Biopharma Co Ltd stock is currently priced at $0.9779, with a 24-hour trading volume of 62,327. It has seen a +2.93% increased in the last 24 hours and a +4.48% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.9734 pivot point. If it approaches the $0.9967 resistance level, significant changes may occur.

Previous Close:

$0.9501

Open:

$1.03

24h Volume:

62,327

Market Cap:

$184.17M

Revenue:

Net Income/Loss:

P/E Ratio:

-2.1916

EPS:

-0.4462

Net Cash Flow:

1W Performance:

+0.81%

1M Performance:

+4.48%

6M Performance:

+54.85%

1Y Performance:

-19.84%

1D Range:

$0.95

$1.03

52W Range:

$0.3503

$1.78

YS Biopharma Co Ltd Stock (YS) Company Profile

Name

YS Biopharma Co Ltd

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

86 10 8920 2086

Address

Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing

Employee

865

Twitter

Next Earnings Date

Latest SEC Filings

YS's Discussions on Twitter

YS Biopharma Co Ltd Stock (YS) Latest News

Short Interest in YS Biopharma Co., Ltd. (NASDAQ:YS) Declines By 40.9% - MarketBeat

MarketBeat

YS Biopharma Co., Ltd. (NASDAQ:YS) Short Interest Update - Defense World

Defense World

Short Interest in YS Biopharma Co., Ltd. (NASDAQ:YSBPW) Decreases By 85.3% - Defense World

Defense World

Little Excitement Around YS Biopharma Co., Ltd.'s (NASDAQ:YS) Revenues - Simply Wall St

Simply Wall St

YS Biopharma to host EGM and appoints new Interim CEO - Investing.com Nigeria

Investing.com Nigeria

YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim ... - PR Newswire

PR Newswire

YS Biopharma Co Ltd Stock (YS) Financials Data

There is no financial data for YS Biopharma Co Ltd (YS). Check out other stocks for more information.

YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. It develops a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.